AUTL

Autolus Therapeutics plc

Fundamental data last updated:October 28, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

GB

Next Earnings Date

11/11/2026

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

 


Analyze AUTL on TradingView

VALUATION

P/E

-1.44

Market Cap ($M USD)

$405.89M

Forward P/E

6.61

PEG

0.07

PRICE TO SALES

3.46

PRICE TO BOOK

5.42

EV / EBITDA

-1.44

5-Year Average P/E

Free Cash Flow Yield

-58.50%

DCF Value

$-25.50

Graham Number

N/A

Price to FCF

-1.71

EV to FCF

-1.34

Earnings Yield

-68.99%

FCF Yield

-58.50%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.05

Next Year EPS Growth Estimate

-$0.78

Next Year Revenue Growth Estimate

$149.40M

Return on Equity (ROE)

-178.58%

FREE CASH FLOW

Operating Margin

-210.76%

Debt-to-Equity

1.12

Piotroski F-Score

3

Altman Z-Score

-4.33

Return on Invested Capital (ROIC)

-57.49%

Current Ratio

4.89

Quick Ratio

4.40

Net Debt to EBITDA

0.40

Interest Coverage

-5.25

Gross Profit margin

15.66%

FCF PER SHARE

$-0.89

REVENUE PER SHARE

$0.44

Analyze AUTL on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to have mispriced Autolus Therapeutics plc, as indicated by its DCF value being significantly negative compared to its snapshot price. The Forward P/E of 7.56 suggests optimism about future earnings, yet the Altman Z-score of -3.27 raises red flags about financial distress. With an earnings yield deeply negative, the company struggles to generate profits. Despite a consensus “Buy” rating, the financial health appears precarious, hinting at potential volatility and risk.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Autolus is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid tech integration could enhance their R&D efficiency. However, execution will be key to capitalizing on these opportunities.

The Bull Case

For a GARP investor, Autolus offers an intriguing proposition with its low Forward PEG ratio of 0.06, signaling potential undervaluation relative to growth. Despite a negative ROIC, the company's high current ratio of 5.94 suggests strong liquidity. The Piotroski F-Score of 3 indicates some financial stability, and the quick ratio supports operational resilience. These factors could appeal to those betting on a turnaround.

The Bear Case

Autolus faces significant structural risks, with a staggering operating margin of -358.89% and a return on equity of -99.00%, indicating severe profitability issues. The Price/Sales ratio of 5.55 and Price/Book of 2.35 suggest the stock is not cheap relative to its fundamentals. The negative FCF yield and interest coverage ratio further highlight cash flow challenges. These metrics paint a picture of a company struggling to maintain financial health.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$8.87

Institutional Ownership %

1-Year Beta

2.14

Insider Buying % (6 Mo)

Distance to 52-Week High

69.18%

Distance to 52-Week Low

22.95%

EARNINGS SURPRISE %

28.57%

50-DAY SMA

$1.99

200-DAY SMA

$1.67

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.